Spots Global Cancer Trial Database for ranibizumab
Every month we try and update this database with for ranibizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy | NCT00540930 | Uveal Melanoma Radiation Retin... Radiation Macul... | Ranibizumab | 18 Years - | Shields, Shields and Associates | |
| Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety | NCT02953938 | Macular Edema S... | Ranibizumab Grid&Direct sho... | 20 Years - | Novartis | |
| Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome | NCT00089765 | Von Hippel-Lind... | Ranibizumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) | NCT01976338 | Macular Edema S... | Ranibizumab 0.5... Sham injection | 18 Years - | Novartis | |
| Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration | NCT00284089 | Subfoveal Choro... | Ranibizumab | 50 Years - | Novartis | |
| Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks | NCT00667472 | Port-Wine Stain | Ranibizumab Pulsed Dye Lase... | 18 Years - | University of California, Irvine | |
| Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) | NCT01976338 | Macular Edema S... | Ranibizumab 0.5... Sham injection | 18 Years - | Novartis | |
| Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration | NCT00504959 | Subfoveal Choro... Secondary to Ag... | ranibizumab | 50 Years - | Novartis | |
| Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety | NCT02953938 | Macular Edema S... | Ranibizumab Grid&Direct sho... | 20 Years - | Novartis | |
| Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration | NCT00284089 | Subfoveal Choro... | Ranibizumab | 50 Years - | Novartis | |
| Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2) | NCT01251978 | Choroidal Melan... | Ranibizumab 2 m... 0.5 mg Ranibizu... | 50 Years - 90 Years | New England Retina Associates | |
| A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. | NCT02034006 | Choroidal Neova... | Ranibizumab | 18 Years - | Novartis | |
| Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema | NCT02055911 | Diabetic Macula... | Ranibizumab | 18 Years - | Federal University of São Paulo | |
| Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) | NCT01976338 | Macular Edema S... | Ranibizumab 0.5... Sham injection | 18 Years - | Novartis | |
| Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety | NCT02953938 | Macular Edema S... | Ranibizumab Grid&Direct sho... | 20 Years - | Novartis | |
| Treatment Of Radiation Retinopathy Trial | NCT00811200 | Uveal Melanoma | ranibizumab triamcinolone a... sham | 18 Years - | Leiden University Medical Center | |
| Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma | NCT00750399 | Radiation Retin... Choroidal Melan... | Ranibizumab ranibizumab | 21 Years - | The New York Eye Cancer Center | |
| Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma | NCT00750399 | Radiation Retin... Choroidal Melan... | Ranibizumab ranibizumab | 21 Years - | The New York Eye Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
